AC
PGNX

Ascend Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ascend Capital’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-159,587
Closed -$800K – 245
2013
Q3 		$800K Buy
+159,587
New +$866K 0.03% 191

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's PGNX Position: Q4 2013 in Review

Ascend Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2013, closing a stake of 159,587 shares — an estimated $800K sold.

Ascend Capital first reported a position in PGNX in Q3 2013 and held it in 1 quarter. The position peaked at $800K in Q3 2013. 70 funds tracked by Wall St. Rank hold PGNX as of Q4 2013.

  • Ascend Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Ascend Capital sold 159,587 Progenics Pharmaceuticals Inc shares in Q4 2013, an estimated $800K.
  • Ascend Capital first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • Ascend Capital's Progenics Pharmaceuticals Inc position peaked at $800K in Q3 2013.
  • 70 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2013.

Based on Ascend Capital's 13F filing for Q4 2013, filed 14 Feb 2014.